[Amiodarone-induced bilateral optic atrophy--a case report].
We report a case of visual loss and bilateral papilloedema under therapy with the antiarrhythmic substance amiodarone, which is used in treatment of refractory and life-threatening supraventricular and ventricular cardial tachyarrhythmias. After excluding intracranial hypertension, local tumors and an inflammatory genesis we consider this case to be an amiodarone-induced toxic opticusneuropathy. Amiodarone, a diiodated benzofuran derivative, is a cationic amphiphilic drug, which is able to cause ceratopathy and neuropathy. The rarely described and less known opticusneuropathy caused problems in differential diagnosis. A brief review about current knowledge of pathophysiology, differential diagnosis and course of illness is presented.
Gobbelé
R
R
Klinik für Neurologie, RWTH, Aachen.
Dahlke
C
C
Mull
M
M
Schwarz
M
M
D000368:Aged; D000638:Amiodarone / Q000009:adverse effects*; D005260:Female; D006801:Humans; D009896:Optic Atrophy / Q000139:chemically induced* / Q000188:drug therapy; D010211:Papilledema / Q000139:chemically induced / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use; D012804:Sick Sinus Syndrome / Q000188:drug therapy; D016896:Treatment Outcome; D058609:Visual Field Tests; D014794:Visual Fields / Q000187:drug effects*
D011239:Prednisolone; D000638:Amiodarone
Amiodaron-induzierte bilaterale Optikusneuropathie. Eine Kasuistik.